Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines
暂无分享,去创建一个
J. Garber | K. Blackwell | F. Meric-Bernstam | T. Yap | J. Stoll | Arya Ashok | E. Mauer | Vanessa M. Nepomuceno
[1] N. Schultz,et al. Therapeutic Implications of Germline Testing in Patients With Advanced Cancers , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Gelber,et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. , 2021, The New England journal of medicine.
[3] David C. Smith,et al. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors , 2021, JAMA oncology.
[4] R. Nussbaum,et al. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome. , 2020, JAMA oncology.
[5] R. Nussbaum,et al. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer , 2020, JAMA network open.
[6] Y. Drew,et al. First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. , 2020, Cancer discovery.
[7] M. Mansukhani,et al. Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology , 2020 .
[8] N. Tunariu,et al. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] L. Siu,et al. Molecular profiling for precision cancer therapies , 2020, Genome Medicine.
[10] Kaanan P. Shah,et al. Integrated genomic profiling expands clinical options for patients with cancer , 2019, Nature Biotechnology.
[11] M. Dwyer,et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 3.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.
[12] J. Sicklick,et al. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study , 2019, Nature Medicine.
[13] Kaanan P. Shah,et al. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay , 2019, Oncotarget.
[14] Jubilee Brown,et al. Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer. , 2018, Gynecologic oncology.
[15] Kaanan P. Shah,et al. Clinical validation of the Tempus xO assay , 2018, Oncotarget.
[16] P. Kantoff,et al. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing , 2017, JAMA.
[17] Marie-Cécile Le Deley,et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.
[18] W. Chung,et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics , 2016, Genetics in Medicine.
[19] Milan Radovich,et al. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers , 2016, Oncotarget.
[20] Tao Wang,et al. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.
[21] Ann M. Bailey,et al. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Lisle E. Mose,et al. Germline Analysis from Tumor–Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings , 2016, Clinical Cancer Research.
[23] Donavan T. Cheng,et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. , 2016, JAMA oncology.
[24] Li Ding,et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.
[25] Wei Yuan,et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.
[26] Nallasivam Palanisamy,et al. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.
[27] Liang Zhao,et al. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy , 2015, Clinical Cancer Research.
[28] Theresa Zhang,et al. Personalized genomic analyses for cancer mutation discovery and interpretation , 2015, Science Translational Medicine.
[29] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[30] Razelle Kurzrock,et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.
[31] A. Knudson. Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.